RxDoctor Payments Data

Abdul Haleem Kazmi, MD

Internal Medicine · Flint, MINPI 1164928230

Payments from drug & device makers

$796in general payments, 2019–2025

Across 50 payments — averaging $15.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$185
  • AstraZeneca$114
  • Exact Sciences$86
  • AbbVie$74
  • Otsuka America Pharmaceutical, Inc.$43
  • Amgen$42
  • plus $252 from 11 others

What the payments were for

  • Food & beverage$796100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$796 in reported general payments places this provider in the 70th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$123,315
Medicare patients
202
Services billed
1,440

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide126$136,122
JardianceEmpagliflozin115$93,287
EliquisApixaban70$62,809
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$36,389
JanuviaSitagliptin Phosphate37$35,547
OzempicSemaglutide27$31,841
XareltoRivaroxaban16$25,137
VraylarCariprazine Hcl16$23,008
Breztri AerosphereBudesonide/Glycopyr/Formoterol29$21,669
EntrestoSacubitril/Valsartan18$14,571
BrilintaTicagrelor25$11,888
FarxigaDapagliflozin Propanediol12$11,805
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate43$11,352
SymbicortBudesonide/Formoterol Fumarate46$10,347
Spiriva RespimatTiotropium Bromide11$7,722

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$25$136,122126 claims
PfizerEliquis$35$62,80970 claims
AstraZenecaBreztri Aerosphere, Brilinta, Farxiga, Symbicort$114$55,708112 claims
GSKTrelegy Ellipta$37$36,38958 claims
MerckJanuvia$18$35,54737 claims
Novo NordiskOzempic$20$31,84127 claims
AbbVieVraylar, Linzess$74$28,84127 claims
NovartisEntresto$18$14,57118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Flint

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →